Hibberd Ashley A, Lyra Anna, Ouwehand Arthur C, Rolny Peter, Lindegren Helena, Cedgård Lennart, Wettergren Yvonne
Department of Genomics and Microbiome Science, DuPont Nutrition & Health, Saint Louis, Missouri, USA.
Department of Kantvik Active Nutrition, DuPont Global Health & Nutrition Science, Kantvik, Finland.
BMJ Open Gastroenterol. 2017 Jul 3;4(1):e000145. doi: 10.1136/bmjgast-2017-000145. eCollection 2017.
The colonic microbiota is altered in patients with colorectal cancer (CRC). We investigated the microbiota composition of patients with colon cancer compared with controls devoid of neoplastic or inflammatory disease and the potential to modify the colonic microbiota with probiotics.
Biopsy samples were obtained from the normal mucosa and tumour during colonoscopy from 15 patients with colon cancer. Subsequent patient-matched samples were taken at surgery from the tumour and nearby mucosa from the patients with cancer, eight of whom had received two daily tablets totalling 1.4×10 CFUs Bl-04 and 7×10 CFUs NCFM. Faecal samples were obtained after colonoscopy prior to starting the intervention and at surgery. In addition, 21 mucosal biopsies from non-cancer controls were obtained during colonoscopy followed by later faecal samples. The colonic and faecal microbiota was assessed by 16S rRNA gene amplicon sequencing.
The tumour microbiota was characterised by increased microbial diversity and enrichment of several taxa including , and compared with the control microbiota. Patients with colon cancer that received probiotics had an increased abundance of butyrate-producing bacteria, especially and spp in the tumour, non-tumour mucosa and faecal microbiota. CRC-associated genera such as and tended to be reduced in the faecal microbiota of patients that received probiotics.
Patients with colon cancer harbour a distinct microbiota signature in the tumour tissue and nearby mucosa, which was altered with probiotic intervention. Our results show promise for potential therapeutic benefits in CRC by manipulation of the microbiota.
NCT03072641; Results.
结直肠癌（CRC）患者的结肠微生物群会发生改变。我们调查了结肠癌患者与无肿瘤或炎症性疾病的对照组相比的微生物群组成，以及用益生菌改变结肠微生物群的潜力。
从15例结肠癌患者的结肠镜检查中获取正常黏膜和肿瘤的活检样本。随后在手术时从癌症患者的肿瘤和附近黏膜采集与患者匹配的样本，其中8例患者每天服用两片总计1.4×10 CFUs的Bl-04和7×10 CFUs的NCFM。在开始干预前的结肠镜检查后和手术时获取粪便样本。此外，在结肠镜检查期间从非癌症对照组获取21份黏膜活检样本，随后采集粪便样本。通过16S rRNA基因扩增子测序评估结肠和粪便微生物群。
与对照微生物群相比，肿瘤微生物群的特征是微生物多样性增加，包括 、 和 等几个分类群的富集。接受益生菌治疗的结肠癌患者在肿瘤、非肿瘤黏膜和粪便微生物群中产生丁酸盐的细菌丰度增加，尤其是 和 属。接受益生菌治疗的患者粪便微生物群中与CRC相关的属如 和 往往减少。
结肠癌患者在肿瘤组织和附近黏膜中具有独特的微生物群特征，益生菌干预可改变这种特征。我们的结果显示通过操纵微生物群对CRC可能具有治疗益处。
NCT03072641；结果
